The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).
Ellis Glenn Levine
Research Funding - Department of Defense
Andres Forero
Research Funding - TRACON Pharma
Tracy O'Connor
No relevant relationships to disclose
Ben K. Seon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - Department of Defense
Manoj A Jivani
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma